A Study of CTA101 UCAR-T Cell Injection in Patients With Relapsed or Refractory CD19+ B-line Hematological Malignancy

Trial Details

NCT ID

NCT04227015

Phase

EARLY_PHASE1

Sponsor

He Huang

Status

RECRUITING

Cancer Type

Lymphoma

Interventions

• CTA101

Locations (sample)

• Hangzhou, Zhejiang, China|30.29365,120.16142

Key Eligibility Criteria

• Inclusion criteria applicable to ALL only:
• Male or female aged ≥ 3 and \<70 years old;
• Histologically confirmed diagnosis of CD19+ B-ALL per the US National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines for Acute Ly…
• Relapsed or refractory CD19+ B-ALL (meeting one of the following conditions):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.